Pharmaceutical companies MSD and Moderna have announced a positive outcome for their phase 3 trial comparing an investigational and individualised mRNA vaccine with anti-PD-1 therapy in melanoma patients.
The combination of intismeran autogene and pembrolizumab (Keytruda) was found to result in “statistically significant and clinically meaningful improvements” in recurrence-free survival and distant metastasis-free survival compared to pembrolizumab alone – although no actual data were presented.
“This represents the first positive phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer therapy, as well as the first phase 3 study to demonstrate a clinically meaningful improvement over Keytruda alone, a standard-of-care immunotherapy, in the adjuvant setting for patients with resected melanoma,” said MSD and Moderna in a joint statement.
To read the full article please click here.
